EP1556391B1 - Lipidanaloge phosphors uretriester - Google Patents
Lipidanaloge phosphors uretriester Download PDFInfo
- Publication number
- EP1556391B1 EP1556391B1 EP03750666A EP03750666A EP1556391B1 EP 1556391 B1 EP1556391 B1 EP 1556391B1 EP 03750666 A EP03750666 A EP 03750666A EP 03750666 A EP03750666 A EP 03750666A EP 1556391 B1 EP1556391 B1 EP 1556391B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phospho
- glycero
- compound according
- glycerol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 phosphoric acid triester Chemical class 0.000 title description 26
- 229910000147 aluminium phosphate Inorganic materials 0.000 title description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 21
- 239000002502 liposome Substances 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- 125000004437 phosphorous atom Chemical group 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- 229940106189 ceramide Drugs 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 150000001982 diacylglycerols Chemical class 0.000 claims description 4
- 150000001783 ceramides Chemical class 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 150000003333 secondary alcohols Chemical class 0.000 claims description 3
- JWBOVDKFGDXGCR-QFIPXVFZSA-N (2s)-2-methoxy-3-octadecoxypropan-1-ol Chemical group CCCCCCCCCCCCCCCCCCOC[C@H](CO)OC JWBOVDKFGDXGCR-QFIPXVFZSA-N 0.000 claims description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 150000001985 dialkylglycerols Chemical class 0.000 claims description 2
- 150000003138 primary alcohols Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 150000002170 ethers Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000005691 triesters Chemical class 0.000 abstract description 3
- 125000003473 lipid group Chemical group 0.000 abstract 1
- 150000003254 radicals Chemical class 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 150000002321 glycerophosphoglycerophosphoglycerols Chemical class 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- CRSOIYXNFFSUFD-UHFFFAOYSA-N 1,2,3-trihydroxypropylphosphonic acid Chemical compound OCC(O)C(O)P(O)(O)=O CRSOIYXNFFSUFD-UHFFFAOYSA-N 0.000 description 1
- AFSHUZFNMVJNKX-LLWMBOQKSA-N 1,2-dioleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-LLWMBOQKSA-N 0.000 description 1
- AFSHUZFNMVJNKX-CLFAGFIQSA-N 1,2-dioleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCC\C=C/CCCCCCCC AFSHUZFNMVJNKX-CLFAGFIQSA-N 0.000 description 1
- BVKFQEAERCHBTG-UHFFFAOYSA-N 17,18,19-trihydroxypentatriacontane-16,20-dione Chemical compound CCCCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCCCC BVKFQEAERCHBTG-UHFFFAOYSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- UDIPIOHLDFSMLR-UHFFFAOYSA-N 2-phenylmethoxypropane-1,3-diol Chemical compound OCC(CO)OCC1=CC=CC=C1 UDIPIOHLDFSMLR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical group OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- ZZILNBYCUYKOLN-NSLPEMCRSA-N [(2R)-2,3-bis[(Z)-octadec-9-enoxy]propyl] 2,3-dihydroxypropyl hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP(O)(=O)OCC(O)CO)OCCCCCCCC\C=C/CCCCCCCC ZZILNBYCUYKOLN-NSLPEMCRSA-N 0.000 description 1
- DRAWQKGUORNASA-XPWSMXQVSA-N [2-hydroxy-3-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(O)COC(=O)CCCCCCC\C=C\CCCCCCCC DRAWQKGUORNASA-XPWSMXQVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 125000002966 glycerophosphoglycerophosphoglycerol group Chemical group 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 238000006140 methanolysis reaction Methods 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940042880 natural phospholipid Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- GWLJTAJEHRYMCA-UHFFFAOYSA-N phospholane Chemical compound C1CCPC1 GWLJTAJEHRYMCA-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Definitions
- the present invention relates to novel phosphoric acid triesters containing apolar lipid structures.
- US 5,855,910 such as US 5,891,714 describe phosphoric triester compounds containing a diacylglycerol, a choline and an alkyl radical. However, the compounds described have no free hydroxyl groups.
- the triesters according to the invention can be used in particular as liposome constituents.
- An object of the invention is a compound of the formula (I) wherein R 1 represents a radical selected from cholesterol, diacylglycerols, dialkylglycerols, acylalkylglycerols, ceramides, primary or secondary alcohols having 12 to 24 carbon atoms or acylglycero-benzyl ethers, R 2 is a radical selected from ethanolamine, N-methylethanolamine, propanolamine , Choline, glycerol, oligoglycerols, glycoglycerols or serine, which may be protective and R 3 is a radical having one of the meanings given for R 2 .
- R 1 represents a radical selected from cholesterol, diacylglycerols, dialkylglycerols, acylalkylglycerols, ceramides, primary or secondary alcohols having 12 to 24 carbon atoms or acylglycero-benzyl ethers
- R 2 is a radical selected from ethanol
- the compounds according to the invention are lipid-analogous phosphoric acid triesters, in particular phosphoric acid triesters with multiple hydroxyl groups per phosphorus atom, in particular at least two hydroxyl groups per phosphorus atom, more preferably at least three hydroxyl groups per phosphorus atom and even more preferably at least four hydroxyl groups per phosphorus atom.
- the phosphoric acid triesters according to the invention contain a radical R 'which contains an apolar lipid structure.
- R ' which contains an apolar lipid structure.
- Suitable structures for R 1 are in particular cholesterol residues, so that preferred phosphoric acid triesters are cholesteryl compounds.
- R 1 Another preferred radical for R 1 is diacylglycerol wherein the acyl groups each independently preferably contain 12 to 28, especially 13 to 27 and more preferably 14 to 26 carbon atoms.
- the acyl radicals may be saturated or mono- or polysubstituted, especially di- or triunsaturated radicals.
- Particularly preferred are the acylglycerols which contain unsaturated fatty acid residues, such as, for example, radicals of oleic acid, linoleic acid or linolenic acid.
- the radical R 1 can furthermore be a dialkylglycerol radical, the alkyl radicals in each case independently of one another preferably having 1 to 28, in particular 12 to 26, even more preferably 14 to 24, carbon atoms.
- the alkyl radicals in the dialkylglycerol radical may be saturated or mono- or polysubstituted, in particular di- or tri-unsaturated.
- R 1 can stand for a ceramide radical.
- Ceramides are endogenous lipophilic amides of the general formula (IV), especially those found in the brain and myelin of the CNS.
- R 4 is a long-chain fatty acid radical, in particular a fatty acid radical having 12 to 28 C atoms
- R 5 is a long-chain alkyl radical, in particular an alkyl radical having 12 to 28 C atoms
- R 6 H.
- R 1 can furthermore be a radical of a primary or secondary alcohol having 12 to 24 carbon atoms, in particular 13 to 22 carbon atoms, where the alcohols can be saturated or mono- or polyunsaturated.
- R 1 may furthermore be an acylglycero-benzyl ether radical, it being possible in particular for such compounds to be used as starting materials for the synthesis of lysophospholipids.
- the radical R 1 can be present in enantiomerically pure form or as a racemic mixture.
- R 2 can stand for all radicals, as they occur in natural phospholipids and sphingomyelins.
- R 2 is an ethanolamine radical, an N-methylethanolamine radical or a propanolamine radical, the radicals being optionally provided with suitable protective groups, for example BOC.
- R 2 can furthermore be a choline radical.
- R 2 is -CH 2 -CH 2 -N + (CH 3 ) 3 .
- R 2 can furthermore be a glycerol residue (-CH 2 -CH (OH) -CH 2 (OH)) and an oligoglycerol residue, in particular a di- or triglycerol residue.
- Other suitable radicals R 2 are glycoglycerols, as well as serine residues. The glycerol and serine residues may optionally also be provided with suitable protective groups.
- R 3 represents a radical having one of the meanings given above for R 2 .
- biologically highly active structures can be formed that act as new cationic lipids have a great meaning.
- Such cationic lipids can be used, for example, for gene transfection.
- the compounds according to the invention are very stable between pH 3 and pH 8 and can be used in particular as liposome constituents.
- the invention further relates to a process for the preparation of a compound of formula (I), which is characterized in that a compound of formula (II) is esterified with a compound of formula (III) HO-R 3 .
- the compounds are derived from phospholipids and are produced, for example by esterification of the phosphoric diester with glycerol:
- These compounds can be produced in different embodiments. They may also contain oligoglycerols, eg instead of glycerol, for example glyceroglycerol, diglyceroglycerol or triglyceroglycerol.
- oligoglycerols eg instead of glycerol, for example glyceroglycerol, diglyceroglycerol or triglyceroglycerol.
- cholesterol phospho-monoglycerol triglyceroglycerol has the following structural formula:
- the compounds of the invention are particularly suitable for the preparation of liposomes or as liposome constituents. They give liposomes special properties, eg long circulating times in the blood, targeted accumulation in the liver or almost exclusive uptake in the spleen. It is also possible with the aid of the phosphoric acid triesters according to the invention to form liposomes with novel properties which have high serum stability, have long circulation times and are enriched exclusively in the spleen. However, long circulation times are also particularly important because the structures are then not, as well-known liposomes, enriched in the liver special other targets, such as the spleen meet or particularly important, can be absorbed by tumor cells. The compounds according to the invention can therefore also be used for the treatment of cancers.
- the invention further relates to a novel synthetic route using the phosphoric acid triester according to the invention as an intermediate.
- a major advantage of the new synthetic route is the possibility of advancing apolar intermediates as far as possible in the synthesis, so that polar structures are introduced only at the end of the process. This will be explained below using an example. Cardiolipins and analogues are complicated structures that are extremely difficult to access synthetically in kg quantities. But with the help of our new synthesis strategy this is quite possible.
- the starting material is 1.2-dipalmitoyl-sn-glycerol, which is converted with phosphorus oxychloride in THF with triethylamine as base in the usual way to 1.2-dipalmitoyl-sn-glycero-3-phosphoric acid dichloride:
- building block III The linkage of building block I with building block II in THF with triethylamine leads to building block III:
- Block III can then be reacted with building block I in the usual way to the direct precursor of cardiolipin, which then by
- Methanolysis is transferred in the dimethyl ester. Catalytic hydrogenolysis then exposes the hydroxyl group on the middle glycerin. The methyl groups are removed by LiBr at neutral pH - the end product is cardiolipin.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
- Seasonings (AREA)
Description
- Die vorliegende Erfindung betrifft neue Phosphorsäuretriester, welche apolare Lipidstrukturen enthalten.
-
US 5,855,910 sowieUS 5,891,714 beschreiben Phosphorsäuretriester-Verbindungen, welche einen Diacylglycerin-, einen Cholin- und einen Alkylrest enthalten. Die beschriebenen Verbindungen weisen jedoch keine freien Hydroxylgruppen auf. J. Keana et al., J. Org. Chem. 1986, 51, 2297-2299, beschreibt als Zwischenverbindung zur Herstellung von Kardiolipinen einen Phosphorsäuretriester enthaltend einen Dipalmitoylglycerin-, einen Glycerin- sowie einen Methylrest. Diese Zwischenverbindung wird dann weiter mit Diazomethan umgesetzt. - Die erfindungsgemäßen Triester können insbesondere als Liposomenbestandteile Verwendung finden.
- Ein Gegenstand der Erfindung ist eine Verbindung der Formel (I)
- Bei den erfindungsgemäßen Verbindungen handelt es sich um Lipid-analoge Phosphorsäuretriester, insbesondere um Phosphorsäuretriester mit mehrfachen Hydroxylgruppen pro Phosphoratom, insbesondere mindestens zwei Hydroxylgruppen pro Phosphoratom, mehr bevorzugt mindestens drei Hydroxylgruppen pro Phosphoratom und noch mehr bevorzugt mindestens vier Hydroxylgruppen pro Phosphoratom.
- Die erfindungsgemäßen Phosphorsäuretriester enthalten einen Rest R', welcher eine apolare Lipidstruktur enthält. Geeignete Strukturen für R1 sind insbesondere Cholesterinreste, sodass es sich bei bevorzugten Phosphoräuretriestern um Cholesteryl-Verbindungen handelt.
- Ein weiterer bevorzugter Rest für R1 ist Diacylglycerin, wobei die Acylgruppen jeweils unabhängig vorzugsweise 12 bis 28, insbesondere 13 bis 27 und mehr bevorzugt 14 bis 26 Kohlenstoffatome enthalten. Bei den Acylresten kann es sich um gesättigte oder ein- oder mehrfach, insbesondere zwei- oder dreifach ungesättigte Reste handeln. Besonders bevorzugt sind die Acylglycerine, welche ungesättigte Fettsäurereste, wie beispielsweise Reste von Ölsäure, Linolsäure oder Linolensäure enthalten.
- Bei dem Rest R1 kann es sich erfindungsgemäß weiterhin um einen Dialkylglycerinrest handeln, wobei die Alkylreste darin jeweils unabhängig voneinander vorzugsweise 1 bis 28, insbesondere 12 bis 26, noch mehr bevorzugt 14 bis 24 Kohlenstoffatome aufweisen. Die Alkylreste im Dialkylglycerinrest können gesättigt oder ein- oder mehrfach, insbesondere zwei- oder dreifach ungesättigt sein. Bevorzugt sind die Reste (Z)-9-Octadecenyl-, (Z.Z.)-9.12-Octadecandienyl-, (Z.Z.Z)-9.12.15-Octadecantrienyl sowie lipophile Grundkörper mit pharmazeutischer Wirkung, wie 1-Octadecyl-2-methyl-sn-glycerin.
- Weiterhin kann R1 für einen Ceramidrest stehen. Ceramide sind körpereigene, besonders in der Hirnsubstanz und im Myelin des ZNS gebunden anzutreffende lipophile Amide der allgemeinen Formel (IV)
- R1 kann weiterhin für einen Rest eines primären oder sekundären Alkohols mit 12 bis 24 Kohlenstoffatomen, insbesondere 13 bis 22 Kohlenstoffatomen stehen, wobei die Alkohole gesättigt oder ein- oder mehrfach ungesättigt sein können.
- R1 kann weiterhin für einen Acylglycero-benzylether-Rest stehen, wobei solche Verbindungen insbesondere als Ausgangsprodukte für die Synthese von Lysophospholipiden eingsetzt werden können.
- In den erfindungsgemäßen Verbindungen kann der Rest R1 in enantiomer reiner Form oder als racemisches Gemisch vorliegen.
- R2 kann für alle Reste stehen, wie sie in natürlichen Phospholipiden und Sphingomyelinen vorkommen. Insbesondere steht R2 für einen Ethanolaminrest, einen N-Methylethanolaminrest oder einen Propanolaminrest, wobei die Reste gegebenenfalls mit geeigneten Schutzgruppen, beispielsweise BOC versehen sind. R2 kann weiterhin für einen Cholinrest stehen. Bevorzugt steht R2 für -CH2-CH2-N+ (CH3)3. R2 kann weiterhin für einen Glycerinrest (-CH2-CH(OH)-CH2(OH)) stehen sowie für einen Oligoglycerin-, insbesondere einen Di- oder Triglycerinrest. Weitere geeignete Reste R2 sind Glycoglycerine, sowie Serinreste. Auch die Glycerin- und Serinreste können gegebenenfalls mit geeigneten Schutzgruppen versehen sein.
- R3 stellt einen Rest dar, der eine der oben für R2 angegebenen Bedeutungen hat. Dabei, können biologisch hochaktive Strukturen gebildet werden, die als neue kationische Lipide eine eine große Bedeutung haben. Solche kationischen Lipide können beispielsweise für die Gentransfektion eingesetzt werden.
- Die erfindungsgemäßen Verbindungen sind zwischen pH 3 und pH 8 sehr stabil und können insbesondere als Liposomenbestandteile Verwendung finden.
- Die Erfindung betrifft weiterhin ein Verfahren zur Herstellung einer Verbindung nach Formel (I), welches dadurch gekennzeichnet ist, dass man eine Verbindung der Formel (II) mit einer Verbindung der Formel (III) HO-R3 verestert.
-
-
- Diese Verbindungen sind in unterschiedlichen Ausführungsformen herstellbar. Sie können auch Oligoglycerine, z.B. anstelle von Glycerin beispielsweise Glyceroglycerin, Diglyceroglycerin oder Triglyceroglycerin enthalten. Schematisch besitzt z.B. Cholesterinphospho-monoglycerintriglyceroglycerin folgende Strukturformel:
- Die erfindungsgemäßen Verbindungen sind insbesondere zur Herstellung von Liposomen bzw. als Liposomenbestandteile geeignet. Sie verleihen Liposomen besondere Eigenschaften, z.B. lange Zirkulationszeiten im Blut, gezielte Anreicherung in der Leber oder auch fast exklusive Aufnahme in der Milz. Mit Hilfe der erfindungsgemäßen Phosphorsäuretriester können auch Liposomen mit neuen Eigenschaften gebildet werden, die eine hohe Serumstabilität aufweisen, lange Zirkulationszeiten besitzen und exklusiv in der Milz angereichert werden. Lange Zirkulationszeiten sind aber auch deshalb besonders wichtig, weil die Strukturen dann nicht, wie bekannte Liposomen, in der Leber angereichert werden sonderen andere Ziele, wie z.B. die Milz treffen oder besonders wichtig, durch Tumorzellen aufgenommen werden können. Die erfindungsgemäßen Verbindungen können deshalb auch zur Behandlung von Krebserkrankungen eingesetzt werden.
- Die Erfindung betrifft weiterhin einen neuen Syntheseweg unter Verwendung der erfindungsgemäßen Phosphorsäuretriester als Zwischenstufe. Ein besonderer Vorteil des erfindungsgemäßen Synthesewegs ist, dass die in früheren Synthesen benutzte Reaktionsführung (a) vermieden wird und nach (b) die wichtige Verbindung 1.2-Dioleyl-sn-glycero-3-phosphoglycerin oder entsprechende Verbindungen unter neutralen Bedingungen freigelegt werden:
R1 = 1.2 - Dioleoyl - sn - glycerin - Ein wesentlicher Vorteil bei der neuen Syntheseführung ist die Möglichkeit, apolare Zwischenprodukte möglichst weit in der Synthese voranzubringen, sodass polare Strukturen erst am Ende des Verfahrens eingeführt werden. Dies wird im Folgenden an einem Beispiel erläutert. Cardiolipine und analoge Verbindungen sind komplizierte Strukturen, die synthetisch in kg-Mengen nur äußerst schwer zugänglich sind. Mit Hilfe unserer neuen Synthesestrategie ist dies aber gut möglich.
-
-
-
-
-
- Methanolyse in dem Dimethylester überführt wird. Durch katalytisch Hydrogenolyse wird dann die Hydroxylgruppe am mittleren Glycerin freigelegt. Die Methylgruppen werden durch LiBr bei neutralem pH entfernt - das Endprodukt ist Cardiolipin.
- Die Beschreibung wird durch die folgenden Beispiele weiter erläutert.
-
- 1) Cholesteryl - phospho - diglycerin
C33 H59 O8 P (MG 614.801) - 2) Cholesteryl - phospho - glycerin - glyceroglycerin
C36 H65 O10 P (MG 688.880) - 3) Cholesteryl - phospho - di - glykoglycerin
C37H67 O10 P (MG 702.907) - 4) 1.2 - Dimyristoyl - sn - glycero - 3 - phospho - diglycerin
C37 H73 O12 P (MG 740.953) - 5) 1.2 - Dipalmitoyl - sn - glycero - 3 - phospho - diglycerin
C41 H81 O12 P (MG 797.061) - 6) 1.2 - Distearoyl - sn - glycero - 3 - phospho - diglycerin
C45 H89 O12 P (MG 853.169) - 7) 1.2 - Dioleoyl - sn - glycero - 3 - phospho - diglycerin
C45H85 O12 P (MG 849.137) - 8) 1.2 - Dioleoyl - sn - glycero - 3 - phospho - di - glykoglycerin
C49 H93 O14 P (MG 937.243) - 9) 1.2 - Dioleoyl - sn - glycero - 3 - phospho - di - glyceroglycerin
C51 H97 O16 P (MG 997.295) -
- 1) R1: 1.2. - Dimyristoyl - glycerin
R2: Cholin
R3: Glycerin - 2) R1: 1.2-Dioleoylglycerin
R2: Glycerin
R3: Methyl -
Molares Verhältnis 1.2 - Distearoyl - sn - glycero - 3 - phosphocholin 40 % Cholesterin 30 % Cholesterin - phospho - diglycerin 20 % Cholesterin - phospho - glycerin, Na(+)-Salz 10 % 100% 1.2 - Distearoyl - sn - glycero - 3 - phosphocholin 50 % Cholesterin 40 % 1.2 - Distearoyl - sn - glycero - 3 - phosphoglycerin, 10 % Na(+)-Salz 100 %
Claims (10)
- Verbindung der Formel (I)
R2 und R3 jeweils unabhängig einen Rest darstellt, ausgewählt aus Ethanolamin, N-Methylethanolamin, Propanolamin, Cholin, Glycerin, Oligoglycerinen, Glycoglycerinen oder Serin, welche gegebenenfalls Schutzgruppen enthalten können,
wobei die Verbindung mindestens zwei Hydroxylgruppen pro Phosphoratom aufweist. - Verbindung nach Anspruch 1,
dadurch gekennzeichnet,
dass R1 für einen Cholesterinrest steht. - Verbindung nach Anspruch 1,
dadurch gekennzeichnet,
dass R1 für einen 1-Octadecyl-2-methyl-sn-glycerin-Rest steht. - Verbindung nach einem der vorhergehenden Ansprüche,
dadurch gekennzeichnet,
dass R2 für einen Glycerinrest steht. - Verbindung nach einem der vorhergehenden Ansprüche,
dadurch gekennzeichnet,
dass R3 für einen Glycerinrest steht. - Verbindung nach einem der vorhergehenden Ansprüche, ausgewählt aus Cholesteryl-phospho-diglycerin, Cholesteryl-phospho-glyceringlyceroglycerin, Cholesteryl-phospho-di-glycoglycerin, 1,2-Dimyristoyl-sn-glycero-3-phospho-diglycerin, 1,2-Dipalmitoyl-sn-glycero-3-phospho-diglycerin, 1,2-Distearoyl-sn-glycero-3-phospho-diglycerin, 1,2-Dioleoyl-sn-glycero-3-phospho-diglycerin, 1,2-Dioleoyl-sn-glycero-3-phospho-di-glycoglycerin, 1,2-Dioleoyl-sn-glycero-3-phospho-di-glyceroglycerin.
- Liposom, enthaltend eine Verbindung nach einem der Ansprüche 1 bis 6.
- Arzneimittel enthaltend eine Verbindung nach einem der Ansprüche 1 bis 6 oder ein Liposom nach Anspruch 8.
- Verwendung einer Verbindung nach einem der Ansprüche 1 bis 6 oder eines Liposoms nach Anspruch 8 zur Herstellung eines Arzneimittels zur Behandlung von Krebs.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10245909 | 2002-10-01 | ||
DE10245909A DE10245909A1 (de) | 2002-10-01 | 2002-10-01 | Lipidanaloge Phosphorsäuretriester |
PCT/EP2003/010870 WO2004031199A2 (de) | 2002-10-01 | 2003-10-01 | Lipidanaloge phosphorsäuretriester |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1556391A2 EP1556391A2 (de) | 2005-07-27 |
EP1556391B1 true EP1556391B1 (de) | 2007-08-01 |
Family
ID=32010077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03750666A Expired - Lifetime EP1556391B1 (de) | 2002-10-01 | 2003-10-01 | Lipidanaloge phosphors uretriester |
Country Status (8)
Country | Link |
---|---|
US (2) | US7592469B2 (de) |
EP (1) | EP1556391B1 (de) |
JP (1) | JP4746319B2 (de) |
AT (1) | ATE368677T1 (de) |
AU (1) | AU2003268895A1 (de) |
CA (1) | CA2500768C (de) |
DE (2) | DE10245909A1 (de) |
WO (1) | WO2004031199A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102006028983A1 (de) * | 2006-06-23 | 2007-12-27 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Phosphorsäurediesteramide |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995001163A1 (fr) | 1992-01-03 | 1995-01-12 | Corbiere Jerome | Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale |
US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
DE19622224A1 (de) | 1996-02-16 | 1997-08-21 | Max Planck Gesellschaft | Phosphatidyloligoglycerine |
US6271209B1 (en) | 1998-04-03 | 2001-08-07 | Valentis, Inc. | Cationic lipid formulation delivering nucleic acid to peritoneal tumors |
-
2002
- 2002-10-01 DE DE10245909A patent/DE10245909A1/de not_active Withdrawn
-
2003
- 2003-10-01 WO PCT/EP2003/010870 patent/WO2004031199A2/de active IP Right Grant
- 2003-10-01 CA CA2500768A patent/CA2500768C/en not_active Expired - Lifetime
- 2003-10-01 EP EP03750666A patent/EP1556391B1/de not_active Expired - Lifetime
- 2003-10-01 JP JP2004540761A patent/JP4746319B2/ja not_active Expired - Lifetime
- 2003-10-01 US US10/529,889 patent/US7592469B2/en not_active Expired - Fee Related
- 2003-10-01 AT AT03750666T patent/ATE368677T1/de not_active IP Right Cessation
- 2003-10-01 AU AU2003268895A patent/AU2003268895A1/en not_active Abandoned
- 2003-10-01 DE DE50307834T patent/DE50307834D1/de not_active Expired - Lifetime
-
2009
- 2009-09-02 US US12/552,799 patent/US8273727B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2500768C (en) | 2012-09-04 |
JP4746319B2 (ja) | 2011-08-10 |
US7592469B2 (en) | 2009-09-22 |
WO2004031199A2 (de) | 2004-04-15 |
US20060039963A1 (en) | 2006-02-23 |
EP1556391A2 (de) | 2005-07-27 |
CA2500768A1 (en) | 2004-04-15 |
DE50307834D1 (de) | 2007-09-13 |
US20100086583A1 (en) | 2010-04-08 |
JP2006501287A (ja) | 2006-01-12 |
WO2004031199A3 (de) | 2004-09-02 |
US8273727B2 (en) | 2012-09-25 |
AU2003268895A1 (en) | 2004-04-23 |
DE10245909A1 (de) | 2004-04-15 |
ATE368677T1 (de) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0188749A2 (de) | Fumarsäurederivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
DE4424530A1 (de) | Pseudoceramide | |
DE2820893A1 (de) | Neue strukturanaloga von phosphatiden und verfahren zur herstellung dieser verbindungen | |
EP0507337B1 (de) | Neue Erucyl-, Brassidyl- und Nervonylderivate | |
EP0880530B1 (de) | Phosphatidyloligoglycerine | |
DE3239858A1 (de) | Neue d-mannitderivate als ausgangsprodukte zur synthese von phospholipiden | |
EP0099068B1 (de) | Neue Glycerinderivate zur Synthese von Phospholipiden | |
EP1102775B1 (de) | Phospholipide mit ungesattigten alkyl- und acylketten | |
WO1999009037A1 (de) | Phospholipidanaloge verbindungen | |
EP1556391B1 (de) | Lipidanaloge phosphors uretriester | |
EP0072936B1 (de) | Neue O-alkyl-O-carbamoyl-glycero-phosphocholine und Verfahren zu ihrer Herstellung | |
EP0483459B1 (de) | Verfahren zur Herstellung von Phosphatidylcholinderivaten | |
DE3639084A1 (de) | Phosphorsaeureester und verfahren zu deren herstellung | |
EP0002062A1 (de) | Phosphororganische Ringverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE19622224A1 (de) | Phosphatidyloligoglycerine | |
EP0663918A1 (de) | Enantiomerenreine phosphorsaureestern als phospholipase a2-inhibitoren | |
EP0072940A1 (de) | Zwischenprodukte zur Herstellung von Glycerinderivaten | |
CH619962A5 (en) | Process for the preparation of synthetic alkyl esters of phosphatidic acids and their structural analogues. | |
DE19520104A1 (de) | Selbstbräunungsmittel | |
WO2007147644A2 (de) | Phosphorsäurediesteramide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050421 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) |
Effective date: 20070809 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REF | Corresponds to: |
Ref document number: 50307834 Country of ref document: DE Date of ref document: 20070913 Kind code of ref document: P |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071112 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071102 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
RAP4 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENS |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071031 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080102 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20071101 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
26N | No opposition filed |
Effective date: 20080506 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20080202 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20071031 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20220916 Year of fee payment: 20 Ref country code: IE Payment date: 20220912 Year of fee payment: 20 Ref country code: GB Payment date: 20220901 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220908 Year of fee payment: 20 Ref country code: BE Payment date: 20220916 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20220621 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 50307834 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MK Effective date: 20230930 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MK Effective date: 20231001 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20230930 Ref country code: IE Ref legal event code: MK9A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20231001 |